文献速递前列腺癌

根治性前列腺切除术后复发接受雄激素剥夺治疗的结局与预后因素

Outcomes and Prognostic Factors in Men Receiving Androgen Deprivation Therapy for Prostate Cancer Recurrence after Radical Prostatectomy.
PubMed 文献 · J Urol · 2018-04-27

该研究基于1987至2007年间单中心2418例根治性前列腺切除术后生化复发并接受雄激素剥夺治疗(ADT)的男性,分析早期进展及生存相关因素。发现ADT启动时PSA≥5 ng/ml和PSA倍增时间<3个月是不良预后因素,而PSA<5 ng/ml和较长倍增时间者风险较低,可能无需立即ADT。

要点

  • ADT启动时PSA≥5 ng/ml预示更差的癌症特异性生存和总生存。
  • PSA倍增时间<3个月是早期进展和癌症特异性生存的不良因素。
  • PSA<5 ng/ml且倍增时间较长者风险低,或可暂缓立即ADT。

核心结论

  • 根治性前列腺切除术后复发启动ADT的男性中,PSA倍增时间<3个月和PSA≥5 ng/ml是早期进展和癌症特异性生存的不良预后因素。
  • PSA≥5 ng/ml还预示更短的总生存。
  • 较长倍增时间和PSA<5 ng/ml与较低风险相关,这些男性可能不需要立即ADT。

研究设计与样本

  • 单中心前瞻性维护登记研究,纳入1987至2007年间根治性前列腺切除术后PSA升高的2418例男性。
  • 早期进展定义为启动ADT后2年内出现临床进展。
  • 主要研究结局为癌症特异性生存和总生存。

主要发现

  • ADT前PSA倍增时间3至<9个月(OR 0.19)和≥9个月(OR 0.10)者早期进展风险较低(各p<0.001)。
  • 癌症特异性生存的独立预测因素包括ADT启动时转移性疾病(HR 2.60)、PSA 5至50 ng/ml(HR 2.68)和PSA≥50 ng/ml(HR 4.33)、倍增时间3至<9个月(HR 0.54)和≥9个月(HR 0.45)(均p<0.001)。
  • 总生存的独立预测因素包括PSA 5至50 ng/ml(HR 3.10)和PSA≥50 ng/ml(HR 5.20)(各p<0.001)。

临床怎么用

  • 对根治性前列腺切除术后复发患者启动ADT前应评估PSA水平和PSA倍增时间。
  • PSA≥5 ng/ml或倍增时间<3个月者提示预后较差,可能需要更积极治疗或密切监测。
  • PSA<5 ng/ml且倍增时间较长者可考虑延迟ADT启动。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We sought to determine clinicopathological factors associated with early progression in men on androgen deprivation therapy as well as cancer specific and overall survival. We also assessed whether certain prostate specific antigen thresholds at androgen deprivation therapy initiation are associated with poorer outcomes. MATERIALS AND METHODS: We identified 2,418 men with rising prostate specific antigen after undergoing radical prostatectomy at a single institution between 1987 and 2007 in a prospectively maintained registry. Early progression was defined as clinical progression within 2 years of initiating androgen deprivation therapy. The primary study outcome was cancer specific and overall survival. RESULTS: The risk of early progression while on androgen deprivation therapy was lower for prostate specific antigen doubling time 3 to less than 9 months (OR 0.19) and less than 9 months or longer (OR 0.10, each p <0.001) prior to androgen deprivation therapy. Independent predictors of cancer specific survival were metastatic disease at androgen deprivation therapy initiation (HR 2.60), prostate specific antigen 5 to 50 ng/ml (HR 2.68) and 50 ng/ml or greater (HR 4.33), and doubling time 3 to less than 9 months (HR 0.54) and 9 months or longer (HR 0.45, all p <0.001). Independent predictors of overall survival were prostate specific antigen 5 to 50 ng/ml (HR 3.10) and 50 ng/ml or greater (HR 5.20, each p <0.001). CONCLUSIONS: In men in whom androgen deprivation therapy was initiated for relapse after radical prostatectomy prostate specific antigen doubling time less than 3 months and prostate specific antigen 5 ng/ml or greater were adverse prognostic factors for early progression and cancer specific survival. Prostate specific antigen 5 ng/ml or greater also predicted shorter overall survival. Longer doubling time and prostate specific antigen less than 5 ng/ml were associated with lower risk and these men may not require immediate androgen deprivation therapy.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Ravi P, Karnes RJ, Rangel LJ, et al. Outcomes and Prognostic Factors in Men Receiving Androgen Deprivation Therapy for Prostate Cancer Recurrence after Radical Prostatectomy. J Urol. 2018. PMID: 29709664. doi:10.1016/j.juro.2018.04.070

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。